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Abstract
The main antigenic site (site A) of foot-and-mouth disease virus (FMDV, strain C-S8c1) may be adequately reproduced by a
15-peptide with the amino acid sequence H-YTASARGDLAHLTTT-NH2 (A15), corresponding to the residues 136–150 of the
viral protein VP1. The eect of amino acid substitutions within A15 on its antigenicity towards monoclonal antibodies (MAb)
raised against antigenic site A, has been studied by means of BIAcore technology, based on surface plasmon resonance (SPR).
Although these antigenicities have previously been determined from enzyme-linked immunosorbent assays (ELISA), the SPR-
based technique is superior in that it allows a fast and straightforward screening of antigens while simultaneously providing
kinetic data of the antigen–antibody interaction. With a view to screening fairly large libraries of individual peptides, we have
inverted the typical SPR experiment by immobilizing the MAb on the sensor surface and using peptides as soluble analytes. We
report the validation of this approach through the screening of 44 site A peptides, with results generally in good agreement with
the relative antigenicities previously determined by competition ELISA. # 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The study of biospecific macromolecular interactions
is central to an understanding of the molecular mech-
anisms involved in viral infection and may help in the
rational design of synthetic vaccines. The antigen–anti-
body reaction involves a series of molecular events
that can be analyzed by dierent biophysical methods
to provide qualitative or quantitative data on the bind-
ing reaction. Optical spectroscopies, particularly those
based on fluorescence, have been widely employed so
far, but with the introduction of surface plasmon res-
onance (SPR) in the early ’90s, optical evanescent
wave biosensors have become increasingly popular for
characterization of reversible biospecific reactions [1–
9]. SPR is an optical detection method that allows to
monitor macromolecular interactions directly, in real-
time and in a label-free mode, in contrast with indirect
methods such as enzyme-linked immunosorbent assays
(ELISA) or fluorescence spectroscopies requiring suit-
able tags. In addition, the ability to provide a real-
time analysis means that not only anity data but also
kinetic data can be obtained. Another attractive fea-
ture is that high purity or large amounts of the biomo-
lecules are not strictly required [1,7–10]. The technique
relies on the covalent immobilization of one interac-
tant (the ligand) onto a modified dextran-coated gold
surface, which forms one wall of a flowcell [11,12]. A
solution of the other interactant (the ligate or analyte)
is injected over this surface at continuous flow.
Monochromatic p-polarized light is directed at the sen-
sor surface and biomolecular binding events are
detected as changes in the specific angle where SPR
creates extinction of light [1,7]. These changes reflect
refractive index changes in the solution close to the
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surface, caused by the increase/decrease of mass due to
analyte association/dissociation to the immobilized
ligand. Therefore, measuring continuously the SPR
angle provides a full record (a sensorgram) of the pro-
gress of the biospecific interaction.
Our research has been focused for some time on
synthetic peptide vaccines against foot-and-mouth dis-
ease virus (FMDV), which causes the economically
most important disease of cattle [13–18]. The high gen-
etic variability of FMDV is responsible for the anti-
genic diversity among FMDV isolates and even within
isolate subpopulations [13,16–19]. This fact is an im-
portant obstacle in the design of eective synthetic epi-
tope-based vaccines. Ideally, such vaccines should
include multiple epitopes to prevent the selection of re-
sistant mutants in the field, and the eects of amino
acid substitutions in infection-involved epitopes should
be well characterized at the molecular level. We have
directed our attention to the various overlapping linear
B-cell epitopes within antigenic site A [13–15,17],
located on the G–H loop of FMDV. This site can be
adequately reproduced by peptide A15 (H-
YTASARGDLAHLTTT-NH2), corresponding to resi-
dues 136–150 of viral protein VP1. We have previously
described the eect of systematic single-residue changes
on the antigenicity of site A [18]. Since we wished to
characterize these antigenic responses not only at equi-
librium but also in kinetic terms, SPR was the method
of choice. However, given the large number of variant
peptides, the only practical way to perform the screen-
ing consists of monoclonal antibody (MAb) immobiliz-
ation and injection of peptide analytes. As direct
detection of analytes smaller than 5000 Da is usually
unfeasible with standard BIAcore protocols [20,21], we
have carried out an extensive optimization of this
approach using 44 of the 240 A15 single mutants as
analytes and anti-site A MAb SD6 as ligand. The gen-
erally good agreement found between biosensor data
and the anities known from ELISA [18] validates
our analytical method.
2. Experimental procedures
2.1. Materials
MAb SD6 stock solution (1.6 mg/ml in PBS, pH
7.3) was obtained as described [14] by Dra. Nuria
Verdaguer (CSIC, Barcelona). The antibody was
desalted and buer-exchanged on Nap-5 Sephadex G-
25 columns (Pharmacia) and the eluate quantitated by
the Pierce BCA protein assay method (Pierce). The
synthesis and purification of A15 analogues has been
previously described [18]. Consumables for the
BIAcore 1000 instrument (CM5 certified sensor chips,
HBS buer, the amine coupling reagents N-hydroxy-
succinimide (NHS) and N-ethyl-N ’-dimethylaminopro-
pyl-carbodiimide (EDC), ethanolamine) as well as the
BIAevaluation 3.0.1 software were all from Biosensor
AB (Uppsala, Sweden).
2.2. Biosensor experiments
2.2.1. Mab pre-concentration and immobilization
SD6 solutions (100 and 50 mg/ml, in either 10 mM
acetate, pH 5.0 or 5 mM maleate, pH 6.0) were separ-
ately injected (30 ml) at 5 ml/min over a non-activated
sensor surface in order to determine which gave the
most ecient pre-concentration of Mab into the dex-
tran matrix. Three SD6 surfaces were prepared using
the standard amine coupling procedure as described by
the manufacturer. Each carboxymethyl surface was
activated with a 35 ml injection (at 5 ml/min) of a
NHS/EDC mixture and SD6 was then coupled at
three dierent densities by exposing each surface to 35
ml injections of SD6 in 10 mM acetate buer pH 5.0 at
concentrations of 50, 5 and 3 mg/ml, respectively.
Nomenclature
FMDV foot-and-mouth disease virus
SPR surface plasmon resonance
ELISA enzyme-linked immunosorbent assay
MAb monoclonal antibody
NHS N-hydroxysuccinimide
EDC N-ethyl-N ’-dimethylaminopropylcarbodii-
mide
RU resonance units
ks apparent kinetic rate constant
ka association kinetic rate constant
kd dissociation kinetic rate constant
R biosensor response (in RU) at a given time
Rmax maximum response (in RU) for a given sur-
face capacity
Rimmob ligand immobilization response
Req extrapolated response (in RU) for the equi-
librium
A analyte
L ligand
CA analyte concentration
KA association equilibrium constant
w 2 chi squared
MW molecular weight
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Unreacted activated groups were blocked by a 30 ml
injection of ethanolamine and remaining non-cova-
lently bound molecules were washed o in a regener-
ation step with a 3-min pulse of 100 mM HCl. The
final densities of immobilized SD6 were 8000, 1700
and 800 RU, respectively (1000 RU corresponding to
a 1 ng/mm2 surface density).
2.2.2. Optimization of the experimental parameters
A few sets of experiments, using A15 as analyte,
were run on the three SD6 surfaces at dierent peptide
concentrations (ranging from 1 to 2440 nM) and flow
rates (5 and 60 ml/min). A 2.44 mM solution of peptide
in 100 mM acetic acid was used as stock, from which
assay samples were prepared by 1000-fold and sub-
sequent serial dilutions in HBS. All experiments were
done in HBS running buer at 258C, using the ‘kinjec-
tion’ mode in order to obtain accurate kinetic data by
decreasing sample dispersion at the injection plugs. To
generate the sensorgrams peptide injections during 7
min followed by 6 min of dissociation in running buf-
fer were used, prior to the regeneration cycle (2-min
pulse with 100 mM HCl).
2.2.3. Kinetic analysis of A15 analogues
Once suitable experimental conditions for kinetic
screening of site A peptides had been established (see
Section 4), a systematic analysis of 43 A15 analogues
was performed, in order to compare biosensor kinetic
data with anities previously determined by compe-
tition ELISA. This analysis was done on a medium
density SD6 surface (1700 RU of immobilized MAb),
at peptide concentrations ranging from ca. 2500 to 150
nM. Stock peptide solutions were quantitated by
amino acid analysis. Sensorgrams were generated at a
60 ml/min flow rate and ‘kinjections’ consisted on a 90
s association step, followed by a 240 s dissociation in
running buer. A 90 s pulse of 100 mM HCl was
applied to regenerate the surface at the end of each
cycle. A pentadecapeptide, A15scr, containing the con-
stituient amino acids of A15 in a random sequence (H-
RAGTATTLADLHYST-NH2) was injected under the
same conditions as a control for instrument artifacts
such as refractive index changes and non-specific bind-
ing.
2.3. Data analysis
Biosensor data were prepared, modelled and fitted
by means of the BIAevaluation 3.0.1. software.
Calculations are carried out by numerical integration
[22] and global curve fitting is done by non-linear
least-squares analysis [23] applied simultaneously to
the entire data set [10,24]. The quality of the fitted
data can be evaluated by comparison between the
modeled and the experimental sensorgrams, as well as
by statistical parameters such as the chi squared, given
by Eq. (1), where rf is the fitted value at a given point,
rx is the experimental value at the same point, n is the
number of data points and p is the number of degrees
of freedom.
w2 
Xn
1
rf ÿ rx2
nÿ p 1
The reaction models and correspondent dierential
rate equations tested are presented in Table 1.
3. Results and discussion
3.1. Optimization of the experimental setup
In our first approach, we tried to overcome the
detection problems to be expected from the low mol-
ecular weight (MW) of our analytes by using a very
dense SD6 surface (8 ng/mm2) and high peptide con-
centrations at a low flow rate (5 ml/min). The sensor-
grams generated under these conditions (Fig. 1a) could
not be fitted to the 1:1 bimolecular model (Table 1) as
inferred from the high and non-random residuals
obtained (Fig. 1b) and from the fact that the associ-
ation rate constant was concentration-dependent (Fig.
1c). Fitting the data to the heterogeneous ligand model
(Table 1), the residuals were lower and randomly dis-
tributed, but the values for ka1 and ka2 were still con-
centration-dependent (data not shown). Since previous
X-ray diraction crystallographic studies have
suggested that SD6 binds to FMDV C-S8c1 through a
single Fab fragment [14,18], we expected a 1:1 SD6/
A15 interaction. Therefore, the inconsistency of the
kinetic data was attributed to the high SD6 density
employed, which generated significant heterogeneity in
ligand accessibility and orientation, as well as favoured
diusion-controlled delivery of analyte to the most
hindered SD6 molecules [25]. Analysis of a broad
range of A15 concentrations at the same flow rate but
over less dense (1.7 and 0.8 ng/mm2) SD6 surfaces did
Table 1
Reaction schemes and dierential rate equations tested. Symbols are
described in nomenclature. Subscripts 1 and 2 refer to the parallel
binding events in two dierent ligand subpopulations
One-to-one reaction:
A+L\ AL
dR/dt=kaCA(RmaxÿR )ÿkdR
Parallel reactions (ligand heterogeneity):
A+L1\ AL1
A+L2\ AL2
dR1/dt=ka1CA(Rmax1ÿR )ÿkd1R
dR2/dt=ka2CA(Rmax2ÿR )ÿkd2R
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not improve the results, the former surface producing
equally inconsistent data and the latter being useless
given the extremely low signal-to-noise ratios (data not
shown).
Therefore, and using again a medium-density SD6
surface (1.7 ng/mm2) and high peptide concentrations
(150 to 2440 nM), we decided to increase the buer
flow rate up to 60 ml/min to obviate the diusion-con-
trolled kinetics which seemed the most probable source
for the persisting deviations from the expected
Langmuirian behaviour. Indeed, consistent and appar-
ently reliable data were now obtained, with a random
distribution of residuals within an interval of ca. 20.5
RU, except for injection plugs (Fig. 2b). Linearity of
ks versus peptide concentration (Eq. (2)) over the 32-
fold concentration range was observed, thus ka was
concentration independent (Fig. 2c).
ks  ka  CA  kd 2
Modeled and experimental curves were virtually
superimposable (Fig. 2a) and a w 2 smaller than 1 was
obtained. Data self-consistency was further confirmed
by the total agreement between the values for the equi-
librium association constant, KA, as obtained from the
ka/kd ratio or from the plot of Req versus peptide con-
centration (Eq. (3), Fig. 2d) for a 1:1 interaction.
From this same plot, a value of Rmax close to that pre-
dicted from the immobilization response, Rimmob (Eq.
(4)) was obtained, thus indicating that the MAb was
fully active.
Req  KA  CA  Rmax
KA  CA  1 3
Rmax  Rimmob  MWL
MWA
4
Table 2
Kinetic data of the interaction between MAb SD6 and 44 site A peptides, corrected for bulk eects (see text). Qualitative relative antigenicities
obtained in ELISA competition assays [18] are represented, with a black box corresponding to IC50>100, a dark grey box to IC50=30 to 100, a
light grey box to IC50=5 to 30 and a white box to IC50 < 5. no, no interaction; nr, non-reliable data
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3.2. Systematic analysis of site A peptides
Having found suitable experimental conditions for
the kinetic analysis of the A15/SD6 interaction, we
applied a similar protocol to the systematic screening
of 43 other A15 analogues. Reduction of ‘kinjection’
times (90 s for association, 240 s for dissociation) low-
ered sample, buer and time consumption, with no
loss in sensorgram quality or kinetic information. The
consistency and accuracy of the fitted kinetic data
obtained for the whole set of site A peptides were in
every aspect similar to those described for A15 under
the same conditions. The stability of SD6 surfaces to
the repeated acidic regeneration cycles allowed us to
screen the entire set over the same surface, without
any detectable loss in MAb activity, thus providing re-
liable comparison among the dierent peptides.
The scrambled 15-mer sequence A15Scr had no
apparent specific binding, but gave rise to a high bulk
response, as observed for the other peptides analysed.
Therefore, the curves obtained for each site A peptide
were corrected by subtraction of the corresponding
A15Scr sensorgrams. A discrete overall improvement
in data quality (lower w 2 values) accompanied this cor-
rection and a general increase in KA was obtained.
This anity increase reflected simultaneously an
increase in ka and a kd decrease (data not shown).
These findings are consistent with the higher prob-
ability of analyte non-specific retention within the dex-
tran matrix when high concentrations are used [8,27].
This binding was probably a ‘response averaging’ of
the biospecific union with the non-specific analyte
imprisonment. The corrected biosensor data for the 44
site A peptides analysed are shown in Table 2, in
which relative antigenicities derived from ELISA [18]
are also represented. The general agreement observed
between both techniques validates our analytical
method for the antigenicity screening of low MW pep-
tides using biosensor technology.
4. Concluding remarks
This investigation has served three major purposes:
1. It shows that BIAcore technology is a powerful tool
to monitor and characterize antigen–antibody inter-
actions even when low MW analytes are used. This
provides a new basis for fast and straightforward
antigenicity ranking of small synthetic peptide anti-
gens.
2. It emphasizes the need for careful experimental
setup and optimization to obviate the problems
usually found in quantitative kinetic biosensor
analysis.
3. It demonstrates the correspondence between pep-
tide–antibody anities as obtained by BIAcore or
ELISA experiments.
Although evanescent wave biosensors are successful
[1–9] in that they provide simple and fast (‘yes’ or
‘no’) answers about the binding of analytes to a ligand,
the quantitative data obtained from them are subject
to several potential artifacts [7,8,25–28]. The most
common sources for such artifacts are heterogeneity in
ligand accessibility and orientation, as well as mass-
transport limitations. Methods for diagnosis and
evaluation of these artifacts, such as global analysis of
data sets generated in dierent surface capacities or
self-consistency tests, are extensively discussed in the
literature [24–32]. Nevertheless, these control tests,
though helpful to ensure internally consistent data,
provide no critical information about the validity of
the kinetic parameters as absolute values. We mini-
mized the undesired artifacts by adapting our exper-
imental setup to high buer flow rate and the
minimum surface capacity possible and thus obtained
self-consistent kinetic and equilibrium data, further
confirmed by previous ELISA experiments [18].
However, caution is still advisable in the evaluation
of such kinetic data. Firstly, one cannot totally com-
pare the events taking place in a biosensor experiment
with those occurring in physiologic media. It must not
be forgotten that although no labels are required in
biosensor analysis, the ligand is still somehow
‘labelled’ by its attachment to a sensor chip. Secondly,
while ELISA provides a valuable check of the re-
liability of biosensor data, one cannot write o the
possibility that mass-transport aects actual ka and kd
values by a similar factor, thus providing thermodyn-
amic constants apparently consistent with equilibrium
experiments. In fact, a preliminary analysis of the
A15/SD6 interaction using IAsys biosensor (a resonant
mirror evanescent wave biosensor where a stirred cuv-
ette, instead of a flowcell, is claimed to overcome
mass-transport limitations) showed virtually the same
anity constant but slightly higher kinetic rate con-
stants [33].
Further experiments in progress include using other
anti-site A MAbs as ligands and a high MW analyte
(a 1:1 conjugate of A15 with a carrier protein) for
real-time competitive analysis [20]. These experiments
will hopefully provide further information on the val-
idity of our methodology.
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